Good morning, ladies and gentlemen, welcome to Veracyte's conference call regarding its pending acquisition of HalioDx, announced earlier today. As a reminder, today's conference call is being recorded. I'd now like to turn the conference over to Tracy Morris, Veracyte's Vice President of Corporate Communications and Investor Relations. You may begin. Thank you, Josh. Good morning, everyone, and thanks for joining us today to review and discuss our pending acquisition of HalioDx, which we announced earlier today. With me today are Bonnie Anderson, Veracyte's Executive Chairwoman, Marc Stapley, Veracyte's Chief Executive Officer, and Vincent Fert, HalioDx's Chairman and CEO. I would also like to point out that today is Marc's first day as CEO of Veracyte. Welcome, Marc. Before we begin, I'd like to remind you that various statements that we may make during this call will include forward-looking statements as defined under applicable securities laws. Forward-looking statements include those regarding our pending acquisition of HalioDx, the expected timing and completion of the acquisition, and our ability to realize the expected benefits of the transaction. Statements regarding future plans, prospects and strategies, financial goals, product attributes and test pipeline, drivers of growth, expectations regarding product manufacturing, biopharma collaborations, reimbursement, and other statements that are not historical fact. Management's assumptions, expectations, and opinions reflected in these forward-looking statements are subject to risks and uncertainties that may cause actual results and/or performance to differ materially from any future results, performance or achievements discussed in or implied by such forward-looking statements. The company can give no assurance that they will prove to be correct and will not provide any further updates on these forward-looking statements. Please refer to our June 1, 2021, press release and the risk factors included in the company's filings with the Securities and Exchange Commission for a discussion of important factors that may cause actual events or results to differ materially from those contained in our forward-looking statements. Our announcement regarding the acquisition of HalioDx is available on our website under Press Releases in the Investor Relations section. A presentation is also available on our website under Events and Presentations in the Investor Relations section. I will now turn the call over to Bonnie Anderson, Veracyte's Executive Chairwoman. Thank you, Tracy, and thank you, everyone, for joining our call to discuss our pending acquisition of HalioDx. The acquisition will further strengthen our long-term growth by providing key strategic capabilities that will enable us to execute on our powerful vision of improving outcomes for patients all over the world at every step of their journey. Marc and I look forward to welcoming Vincent and the HalioDx team to Veracyte and are thrilled about layering HalioDx's business into the company. The acquisition of HalioDx will be a key piece of the strategic puzzle that will enable us to execute on our powerful global vision. When we acquired the global rights to the incredible nCounter platform in 2019, we knew that we would need to bring under our control the ability to develop and manufacture IVD test kits, and we would need to establish a European headquarters. We're really excited that HalioDx will give us both of these important elements for our business. HalioDx, with its development and manufacturing infrastructure and operations in Europe, will enable our reach into global markets, while also further expanding our scientific capabilities into the emerging immuno-oncology field and broadening our testing menu to address eight of the 10 top cancers. HalioDx has developed a unique biopharma partnering ecosystem for the identification of clinically relevant biomarker signatures, the demonstration of their utility in clinical trials, and the development and commercialization of resulting IVD and companion diagnostic tests. Additionally, as you will see here on slide four, we believe this acquisition will be accretive to our revenue growth in 2021 and beyond by helping us accelerate test menu development on our nCounter platform for global distribution, as well as expanding our scientific expertise into the emerging immuno-oncology field. We are executing on an exciting vision that is now becoming a reality, as you can see illustrated on slide five in our presentation deck. With the acquisition of HalioDx, we will complete the puzzle and expand on our growth opportunities along three strategic pathways. Firstly, global growth, expanding from a centralized lab business in the U.S. only to a global lab and instrument kit business that we entirely control from end to end. Secondly, scientific excellence, extending our technology to advance our pipeline of high-value genomic tests and to fuel biopharma partnerships to bring to Veracyte the innovative Immunoscore platform to harness the patient's immune system to assess risk and patient outcomes. Thirdly, menu expansion, expanding to address eight of the top 10 cancers by U.S. incidence by adding colorectal to our portfolio, answering important questions along the patient care continuum for this terrible disease that impacts over 160,000 patients in the U.S. annually. When I founded Veracyte in 2008, we had a vision to become a global leader in diagnostics for cancer and other diseases. We began with whole transcriptome arrays and machine learning and then migrated our tests to RNA whole transcriptome sequencing as the cost of sequencing declined. We focused on unmet needs and important questions in three disease areas: thyroid cancer, lung cancer, and interstitial lung diseases. First improving diagnosis and then using our robust scientific platform to address additional questions along the care continuum, including informing treatment decisions and upstream, improving early detection in lung cancer. The acquisition in December 2019 of the exclusive global diagnostic rights to the nCounter Analysis System gave us a powerful platform for making our advanced genomic tests available to physicians and their patients in global markets where laboratories favor a distributed model. We also expanded our menu through that transaction to include breast cancer and lymphoma. Our acquisition of Decipher further expanded our testing menu with market-leading diagnostics in prostate cancer and bladder cancer and a pipeline test in renal cancer, enabling us to address many of the leading cancers by incidence. With the recent acquisitions and strategic initiatives completed and the pending addition of HalioDx, Veracyte is well positioned to further accelerate our global growth for its cancer tests. At this point, I'd like to introduce you to Vincent Fert, the Chairman and CEO of HalioDx, to introduce you to the company. Vincent? Thank you, Bonnie. First, on behalf of the entire HalioDx team, we are excited to become a Veracyte company and the European headquarters for Veracyte. Like Bonnie, Marc, and the rest of the Veracyte team, we share the same vision to improve outcomes for patients all over the world at every step of their journey. Very much like Veracyte, the founders and management of HalioDx have significant experience in creating high-quality diagnostic products, including working with biopharma to enhance patient care. In addition, we have been developing and manufacturing complex diagnostic products for the last 15 years. The HalioDx leadership team, as shown on slide six of the deck, is comprised of a unique blend of sound industry experience with a track record of successes. In the early 2000s, this group founded Ipsogen to develop molecular monitoring of blood cancer. The company progressed rapidly, went public in 2008, and developed a significant IVD business in both Europe and the U.S. Ipsogen was then acquired by QIAGEN in 2011 for $100 million. Over the next four years, the team developed the personalized healthcare business of QIAGEN and [BioExtension] and then in 2015, spun off HalioDx. Turning now to slide seven. HalioDx is positioned as a pioneering leader in the immune response diagnosis of cancer based on a strong patent portfolio developed by our Co-Founder, Jérôme Galon. We are a commercial-stage immuno-oncology diagnostic company providing oncologists and drug development organizations with first-in-class diagnostic products and services to guide cancer care and contribute to precision medicine. We provide a unique range of immune assessment solutions, including our flagship Immunoscore assay for assessing the immune contexture of a tumor as a key determinant of patient outcomes and response to cancer treatments. We have developed a unique biopharma partnering ecosystem for the identification of clinically relevant biomarker signatures, the demonstration of their utility in clinical trials, and the development and commercialization of resulting IVD and companion diagnostic tests. We operate two CLIA-certified laboratories in the United States and France, as well as a facility in France that develops, manufactures, and distributes in vitro diagnostic products. We are excited about the acquisition by Veracyte for several reasons. For HalioDx, Veracyte's resources, capabilities, and strong reputation will help us to expand the market reach for our tests and advance our pipeline. We believe the combination of our extensive manufacturing capability, our scientific expertise in immuno-oncology, and our colorectal diagnostic products are complements to Veracyte's business and enable Veracyte to execute on its global vision. Let me now turn the call to Marc to walk you through the strategic pathway. Marc? Thank you. Thank you, Vincent, and good morning, everyone. I'm thrilled to share details about our acquisition of HalioDx and can't imagine a better way to kick off my first day as Veracyte's CEO by solidifying this key element of the Veracyte vision. Let me reiterate the three pathways that underscore the strategic rationale for the acquisition. First, as you will see on slide eight, HalioDx provides European development, manufacturing, and operational capabilities to support our global testing and menu expansion, giving Veracyte the capability to own the manufacturing of the test kits that run on the nCounter Analysis System. This will give us end-to-end control of our distributed test business, critical to ensure that we can expand globally and meet our customers' needs as we scale. With this acquisition, we will plan to transition manufacturing of our kits, currently produced by NanoString, to HalioDx's facility in Marseille, France. This will further accelerate the expansion of our test menu on the nCounter platform for Europe and other strategic global markets. This will also give us the opportunity to improve gross margins on the nCounter products. We will be prioritizing new tests for the nCounter and excited about our plans to adapt Envisia, the first of our legacy tests, onto the instrument by the end of 2021. As you know, we recently launched exciting data for our Percepta Nasal Swab for early lung cancer detection, which we expect to develop on the nCounter in 2022 and make available in global markets the following year. Additionally, given our recent acquisition of the Decipher business, we will explore opportunities to move our prostate and bladder cancer tests onto the nCounter instrument to expand their reach into global markets. Our acquisition of worldwide diagnostic rights to the nCounter platform and HalioDx's development and manufacturing capabilities together allow us to access a long-term global market of approximately $50 billion. HalioDx provides the European headquarters to support our global expansion and to simplify nCounter test distribution in international markets. Secondly, moving to slide nine, HalioDx deepens our scientific capabilities to expand our diagnostic offerings and fuel our biopharma services business. We are a unique and complementary immuno-oncology biomarker analysis technology that supports our vision of answering important clinical questions along the patient care continuum. HalioDx's technology has the potential to enhance our tests for patients at every step of their journey in cancer and serves as a platform to grow our biopharma partner business. The addition of immune biomarkers that are complementary to tumor genomics can help further inform patient care, from treatment decisions to risk for recurrence, and help improve outcomes for patients. Slide 10 illustrates HalioDx's Immunogram multimodal analysis platform for guiding immuno-oncology clinical development. It is a biomarker approach that enables a 360-degree view of the immune tumor microenvironment, allowing the quantification of various immune and non-immune cell types inside and around the tumor bed from a small amount of tumor sample. The Immunogram platform can help predict patient response to immunotherapy and is synergistic with our biopharma partnering efforts, which leverage our large biorepository of genomic content built from whole transcriptome sequencing. In December 2019, a partnership with Kite Pharma, a subsidiary of Gilead, allowed HalioDx to position itself among the major players in the analysis of the tumor microenvironment and as a strategic partner of the biopharmaceutical industry developing immunotherapy, a field that is, as you know, rapidly expanding. Now, looking at slide 11, HalioDx's flagship Immunoscore assay evaluates the immune contexture of a tumor at a basic level, looking at a patient's lymphocytes to determine how those cells are physically infiltrating the tumor, and from this, producing a score that reflects how activated the patient's immune response is. Finally, as you can see on slide 12, HalioDx expands our current cancer testing market into colorectal cancer, which is the third pillar of our strategic rationale. With the addition of HalioDx's Immunoscore IVD test, which leverages the immuno-oncology platform previously described, Veracyte is now positioned to address eight out of the top 10 cancers by U.S. incidence. We believe this broad portfolio positions Veracyte as a leading global cancer diagnostics company. As shown on slide 13, Immunoscore provides us with a near-term commercial opportunity in colorectal cancer, which we estimate is approximately a $2 billion market. Immunoscore Colon is a commercial stage test today, addressing unmet needs for approximately 300,000 colon cancer patients, and with the potential to expand into later stage colon cancer and rectal cancer. HalioDx also has in their pipeline development projects to expand further into other indications beyond colorectal cancer. I'm excited about this acquisition and about the many ways it helps us execute on our powerful vision. Layering this step on top of the recent Decipher acquisition completes, for now, the vision for Veracyte that Bonnie and I believe will achieve our potential for growth. We clearly have a lot to get through over the next year or so as we complete the integrations, transition manufacturing to Veracyte, and launch our new products. In my role as CEO, I'm excited to bring my experience building and leading complex global organizations, and I'm confident we can put these pieces together. To ensure success, Bonnie has agreed to lead the HalioDx acquisition and strategic integration. I look forward to working closely with Bonnie on this as we continue to greatly benefit from her leadership and deep experience in immunology from her 18-year tenure at Beckman Coulter. Of course, I also look forward to welcoming the HalioDx employees to Veracyte and starting to work together to achieve our vision. At this point, I will now turn the call back over to Bonnie. Thank you, Marc. Moving to the deal terms and financials on slide 14 in our deck, you will see that Veracyte has negotiated to purchase HalioDx for approximately EUR 260 million in cash and equity. The transaction, which has been unanimously approved by Veracyte's Board of Directors and is fully supported by the HalioDx Board of Directors, is expected to close in the third fiscal quarter of 2021, subject to the required works council consultations and the satisfaction of customary closing conditions. Looking at slide 15, HalioDx grew its 2020 total revenue by 43% to EUR 19.9 million, compared to EUR 13.9 million in 2019, and its total revenue in the first quarter of 2021 was approximately EUR 5.5 million. For the remainder of 2021, HalioDx's revenue contribution to Veracyte will be dependent on the transaction close date, the U.S. dollar-euro exchange rate, and transaction and purchase accounting. When the transaction closes, we will incorporate HalioDx's financials into our guidance. Having said that, Veracyte expects the acquisition of HalioDx to be accretive to its revenue growth in 2021 and to expand the near-term addressable market for Veracyte's current and pipeline tests. Turning to slide 16, I could not be more enthusiastic to be taking on the Executive Chairwoman role, working with Marc and the HalioDx team to realize the potential of the vision we set out to accomplish almost 14 years ago. With the completion of recent acquisitions and strategic initiatives over the last couple of years, Veracyte is well-positioned to accelerate growth in the approximately $50 billion long-term global market for our cancer and other high-value diagnostic tests. In closing, we want to remind you of the strategic rationale, key terms, considerations, and timing of this transaction, which are all summarized on slide 17. We are confident, with the addition of HalioDx, we will even be better positioned to improve outcomes for patients all over the world at every step of their journey. We look forward to delivering incredible value to patients, physicians, employees, and to you, our shareholders. With that, we will open the call for questions. Thank you. As a reminder, to ask a question, you will need to press star one on your telephone. To withdraw your question, press the pound key. Please stand by while we compile the Q&A roster. Our first question comes from Brian Weinstein with William Blair. You may proceed with your question. Hey, guys. Good morning. Just a couple of questions. Bonnie, just starting out with you guys have obviously a ton going on right now with the launch of n asal swab coming up at the end of the year. You've got the Decipher integration that is ongoing. You've got a base business that is obviously also moving forward pretty rapidly. You also had management changes at the top. Can you just talk about the company's ability to take something like this on at this time of the company's development with so much else going on here? How are you guys going to manage this sort of integration process? I understand you're staying on and you'll be sort of managing it, but in general, this seems like an awful lot for the organization to be able to take on at this point. Can you just sort of talk through that a little bit for us and give investors some comfort there? Hey, Brian, it's Marc. I'll start since it's my first day on the role here and give you my perspective, and then, Bonnie, please do weigh in as well. You're absolutely right, and you picked up on the key point. We have got a lot going on. I think there's always a lot going on in a company like ours that is fast-moving, growing, and has laid out a strategic vision and is executing on that. Having said that, we've put in place a lot of the steps necessary to make sure that everything that we're doing, including this acquisition, is successful. You mentioned our nasal swab and the other products that we're launching this year. We've got the full team engaged on very successful launches, and we have a lot of talented people within Veracyte that are leading those. The Decipher integration is going extremely well. Of course, we have a very experienced leader at the helm there in Tina, who's also taken on our thyroid business as well. That's all covered. As far as the management changes are concerned, if you think about the role that Bonnie and I will play, this sets us up really well, actually, for this acquisition. Of course, we've had this in mind. I'm going to run the company starting from today. Bonnie is going to take on a key role with the acquisition. We've talked before about Bonnie's role going forward as a strategic advisor to me and also working on strategy and business development initiatives and opportunities. This is the first where she's going to take a very key role, leading the acquisition to closure and then leading the integration, making sure that we optimize the success of this wonderful acquisition of HalioDx. Bonnie? I'd just like to add that what other company has been able to lay out a long-term vision, execute on the acquisitions needed to achieve that vision, and along the way, attract what will be following the closure of this deal, four current and former CEOs on board helping to make that a reality. I think that helps to illustrate how excited I am as an ex-CEO. Tina staying on as well to lead, and now we'll have Vincent Fert, who I've known for a long time, and he'll do an amazing job leading the HalioDx effort to align and strengthen and help us achieve the success we're looking for. Great. Thank you for that. I appreciate those comments from both of you. In terms of the revenue that the company posted, the $20 million last year, can you break that down? If you did already, sorry if I missed it. Can you break that down between the Immunoscore and then the other products that the company has in the pipeline? I'm sorry, anything that they're working on with pharma partners, just to give us an idea about where that revenue is coming from. Yeah. We're not going to break down the individual components of that revenue. Halio is obviously private, and so there's not much more detail that we're going to provide on that. What I will say is, once the transaction closes, we'll incorporate their financials into ours and give a little bit more color commentary at that point in time. Yeah, we're not going to do the individual breakouts unfortunately, at this time. Okay, the last one from me. Can you talk at all about the R&D that's going on at Halio right now in terms of what types of relationships they currently have with pharma and then anything else that they're developing themselves from a diagnostic platform? Is that something that you guys would be able to provide some insight into? Yeah, I mean, I'll ask Vincent on the call. I'll ask Vincent to give a high-level overview of some of the R&D activities that you're asking about. Vincent? Yeah, sure. The first part of your question, we are working closely with biotech and pharma. What I can say is that all these companies go to us because we are experts in the immune biomarkers part, and they all developed immunotherapies, whatever, like CAR T-cell or vaccines. Okay? We are one of the few experts in immune biomarker that can help those companies understanding mechanism of action and stratifying patients for their clinical trials. Thanks, Vincent. Obviously, we talked in the presentation, in the prepared remarks about the work that's going on with the Immunoscore and the pipeline opportunity there. I think the other thing to note is we're really excited to actually bring our capabilities together. A lot of the expertise that HalioDx has in immuno-oncology is complementary with our expertise in cancer genomics and the large biorepository genetic content that we've got. Putting that together, we think enhances our opportunity to work with biopharmaceutical industry and create a really unique offering. I agree. When you combine the biology of the tumor with the biology of the patient's response to that tumor, you're answering the 360-degree question around how that individual patient might respond. It's a really exciting combination. Thank you, guys. Thank you, Brian. Thanks, Brian. Thank you. Our next question comes from Puneet Souda with SVB Leerink. You may proceed with your question. Hi, Marc. Bonnie. Thanks for the question. From what I see, there are key components here. One is the transition of the nCounter kits manufacturing towards Veracyte's test and the expansion. Second is your expansion into Europe and with the CLIA labs here and the addition of the Immunoscore test and the pharma services that HalioDx is bringing to the table. Maybe just to refresh investors, could you update us on what is the status of nCounter kits manufacturing today? What is the current arrangement with manufacturing with the existing kits and any obligations that you need to fulfill there before transitioning to the France side? Also, if you could provide any geographic breakdown for what Halio is doing currently in Europe versus U.S.? Yeah. Just to cover on the nCounter, I'll ask Bonnie if she wants to provide more details. When we completed that acquisition in 2019, we knew that we would have to make the transition of the manufacturing to Veracyte at some point in time. We've been spending our time thinking through that, working through that, and as you can see from this announcement today, we're now making great progress on that. There's a lot of work ahead of us. We're going to move quickly to make that transition happen, and that's one of the things obviously that Bonnie's going to be leading for us. Bonnie, I don't know if you want to give any more details on the. We have secured a contract manufacturing from manufacturing, of course, at the time of the transaction, and so we have been working with them on the development program for Envisia moving forward and have plans on beginning to supply kits with Envisia at the end of the year. We think it could take up to two years to get the manufacturing fully transitioned, so the timing could not be better to begin that process. As I think our original timeline was to notify in a year, which would mean three to four years to get that done. We're coming up on the two-year window. Everything is lining up perfectly to achieve that goal of taking it over. Thank you, Bonnie. On HalioDx's geographical split, I'll ask Vincent to give kind of a high-level view. We're not going to break out the numbers, but a high-level view of the activities geographically. Vincent, do you want to just give a quick overview? Are you on mute? Vincent, you there? Oh, sorry, Marc. I'm here. On our biopharma activity, the majority of our customers are European-based. We do have a few U.S. customers, Kite, for example. Indeed, the perspective of joining Veracyte will open us new perspective for the U.S. market for that. Considering the Immunoscore diagnostic in colon, we are in the pre-launch phase, and we were focusing a wide focus to get the reimbursements in the U.S., and I think the support and the expertise of the Veracyte team will be very important here. Concerning our IVD activity, it's basically a lot of European companies. I would say our activity is really European-centric. Got it. That's very helpful. If I could follow up, Marc, Veracyte has traditionally focused on classifier tests and done a really solid job at that. It seems like you're growing more later stage colorectal cancer as well as non-small cell lung cancer. Could you maybe help us understand how is Immunoscore situated in the market, and how is it positioned versus the current therapy management products such as the FoundationOne CDx or Guardant360 products or the emerging MRD products, the liquid biopsy products from Natera and Guardant? Can you help us understand how it's positioned versus those in the market, and what expectations do you have for the overall expansion of the Immunoscore product line? Yeah, just kind of going back, our original vision here is to improve outcomes for patients all over the world at every step of their journey. While we focused on particular areas initially here, our goal is to expand across the care continuum. You saw that with the nasal swab, which as you mentioned helps, or as mentioned earlier, helps early detection in lung, and of course, that can even go further upstream. I would say, then the Immunoscore assay and the immuno-oncology capabilities that HalioDx brings allows us to address even more of the care continuum. Bonnie, I don't know if you want to give some specifics around the question and the market positioning there. Yeah, there's a couple of things, and Vincent may want to comment as well, but what I love about their technological approach is that it's a platform technology. You can build the Immunoscore assay essentially across the entire landscape of cancers. The lead product, which is, as Vincent mentioned, going through the MolDX coverage process right now, is indicated for Stage II and Stage III colon cancer patients, where you're looking at the infiltrate of the immune cells and being able to determine based on the strength of a patient's immune system, whether or not you need to use more aggressive treatment. As I was saying earlier, this is bringing the full picture of the biology together. Not only looking at the biology of the tumor, which we and many others are doing and have done for a long time, but now combining that with what is the host's immune response to this, and if it's very strong and you have a very high Immunoscore, then you potentially can be less aggressive in treatment. Of course, if the patient's immune status is very low to the tumor, then more aggressive treatment would be warranted. They've got a lot of data on a number of different areas, but the lead test is in colon cancer. Really exciting new area to complement everything we're doing, and again, just helping to advance the program and put them in the care continuum for patients. Thanks. Got it. That's very helpful. Last one, if I could squeeze in. Around the sales force, do you expect to build out the core oncology sales force to offer this product in U.S. and Europe, and also with lung cancer specialists? By that, I mean the Immunoscore product. Thank you. Well, we clearly have the benefit of the existing HalioDx sales force and business development team, and then of course, we'll be able to bring to bear the greater Veracyte team to that. In terms of how we grow that in the future, that will be part of our integration planning and our planning for the rest of this year, which we'll update on again once we complete the acquisition. Okay. Great. Thanks. Thanks. Thank you. Our next question comes from Tejas Savant with Morgan Stanley. You may proceed with your question. Hey, guys. Good morning, and thanks for the time this morning. Don't have too many, just a couple of quick cleanup questions here, Marc. In terms of that Halio revenue step-up that you saw in 2020 versus 2019, would you be willing to share some color on any specific sort of contracts with biopharma or any other drivers that you'd like to highlight there, and also the momentum you're seeing here continuing into the first quarter for the business? Yeah. I mean, probably no specific commentary. Vincent, if you want, feel free to add. I would say, clearly what we've seen here is HalioDx is gaining traction. I'd say that traction is across the elements of the business, including the biopharma and then, of course, with launching the Immunoscore. That's been the key driver, and then we provided the first quarter actuals, which I think demonstrate that traction is continuing. Vincent, I don't know if there's something you want to add, but please feel free. Yeah. Marc, thank you. I mean, it was perfect. I mean, we see a very dynamic development of our biopharma business. We have seen that in 2020, and we will see that also this year. Got it. In terms of just the headcount split between Europe and the U.S., I'm assuming, is it sort of 70/30, 80/20 Europe versus the States? Bonnie, I mean, if you could elaborate on how you envision the Richmond site sort of unfolding on a go-forward basis. Will you use it to expand some of what you do in your current facility in the States, or will that exclusively be for nCounter chip manufacturing as well? Yeah, I would start on the first one. Headcount is significantly biased to France. Yeah. That's my lab and sales and support team for biopharma and Immunoscore in the U.S. I mean, as we go back to the strategic rationale we laid out, for us, finding a company of this size and this caliber with a new area that is one of the hottest emerging areas in science that allows us to acquire European operations with global regulatory and quality processes in place that is ready-made with the addition of the capital and things that we'll need to do to transfer our specific technology, this was just an awesome find. We think there really could not be a better fit for what we need operationally, and then also the new science area is just kind of icing on the cake. Got it. Very helpful. Thanks, guys. Thank you. Thank you. Thank you. Our next question comes from Thomas Flaten with Lake Street Capital Markets. You may proceed with your question. Good morning, thanks for taking the questions. I apologize if I missed this, Bonnie, but could you walk us through within your new general manager organizational structure, how Halio will fit into that or how you anticipate fitting into that? It's Marc here. I'll answer, Bonnie, if I miss anything, please fill in the gaps for me. Initially, what we're planning to do here is to keep HalioDx running as HalioDx as a business, they've got a very capable leadership team that Vincent walked you through. We have a slide on that. That team will become part of the senior leadership, of course, of the company. For the actual integration of the manufacturing, Bonnie will take that on as part of her activities going forward. We'll see how that shapes out. Of course, I'm going to continue to fill out the leadership team here at Veracyte, including getting a world-class CFO as well. I'm day one on the job, so I haven't looked across the rest of the organization here in terms of how we structure, but I love the general manager structure that Bonnie put in place. I believe in it. I think it's the right one. If anything, there'll only be minor adjustments as we bring in HalioDx to that. Just one quick question on Immunoscore. Is that entirely immune-based, implying that it would be tumor agnostic? Are there any limitations to the tumor types that you could expand into with that? That's what is one of the most incredible things about the technology. It's measuring the contexture of the immune system at the tumor microenvironment, questions being asked every day now in the growth funnel of immunotherapy. We'll be in the heart of that. We'll be able to complement the platform technology and its utility across tumor areas with the potential to focus on lung cancer, prostate, and colon, which will complement some of the large-scale biorepositories and information we have on tumor biology, especially in lung cancer and prostate, and use some of our U.S. resources. This will be part of what I get to help with is, how do we integrate this so that we're benefiting from the areas of strength across our business today, utilize this new technology area to augment our portfolios and our reach into biopharma, especially in lung cancer, prostate, and colon, where we'll have a foothold. At the same time, set the team up so that we can get the operation integrated, the manufacturing up and running. It'll be a fun project for me. I'm first day on the job too, and I'm looking to knock the ball out of the park for Marc as his Executive Chairwoman. Thank you, Bonnie. Thanks, guys, for taking the question. Congrats. Thanks. Thank you. Our next question comes from Mike Matson with Needham & Company. You may proceed with your question. Yeah, good morning. Thanks for taking my questions, and congrats on the deal here. I guess, on slide 15, I just wanted to ask about the HalioDx growth that's shown on there. Is that all organic? It's pretty amazing to see that they grew 43% during 2020 given the pandemic. It almost seems like there's a bit of an inflection happening in the growth rate there. Maybe you could talk a little bit about that. Yeah. It is organic. Correct me if I'm wrong, Vincent, but yes, it's entirely organic, and that's the same thing. Very impressive during that particular year that the company continued growth. Vincent gave a little color on the biopharma opportunities that have continued to gain traction in 2020. At this point, I think those are the key elements of that growth. Okay, thanks. Just wondering about the, since the manufacturing capacity is important part of the deal here, can you talk about how much space they have and how much runway you have there before you'd have to expand that as you move on to the nCounter platform or expand the test availability there in Europe? Yeah. You can see a little bit of this on slide eight, but the facility is obviously relatively significant. I think close to 30,000 sq ft. Correct me if I'm wrong, Vincent. No. Yes, that's right. Yeah. Good. Obviously the capacity supports the current business, and the growth that they've experienced and there's plan to support the future growth. Obviously, one of the key things that we're going to have to do, and then of course, the manufacturing transition will require changes to that manufacturing facility capability and so on. That's part of the key planning here. It's going to take some time to get through that. One of the changes we're going to have to make is ensure that there's sufficient capacity to meet Veracyte's needs for the foreseeable future. Planning ahead, I think is the key there, and we're going to put a lot of our attention and effort into making sure we do that right. I wouldn't say the volume of manufacturing that's required is going to be part of the plan, and we're going to obviously invest to achieve that. Okay. Thank you. Thank you. As a reminder, to ask a question, you'll need to press star one on your telephone. Our next question comes from Paul Knight with KeyBanc Capital Markets. You may proceed with your question. Hi, Marc. Could you update us, I think you talked about the nCounter program, but just refresh us there. Bonnie, your insights you've gained with nCounter by looking at HalioDx. They've obviously achieved success there. You seem obviously a step up here with nCounter, but could you give us a refresh there? When you say update on the nCounter program, you mean our plans to transition- Yeah. -products to nCounter? Yeah. Yeah. Obviously our first product to transition is Envisia, and that'll be this year. Then we talked about when we launched our data for the Percepta Nasal Swab, that will be our next product, which will be transitioned next year, commercial the following year. Then, of course, I think I mentioned this in the prepared remarks as well, but Decipher products are potential great products because the European market in particular is a great potential market for that product. We'll be looking to transition those. In addition, don't just think of this as transitioning, but developing new products as well, that go straight to our own manufacturing with HalioDx for the nCounter platform. Halio has had the opportunity through a spin-out relationship they've retained with QIAGEN and several other relationships for the contract development of IVD and companion diagnostic tests, and then the follow-on manufacturing of those. Over the years of experience, including prior to that, more than 15 years experience developing these kind of programs, and what's really key is that they have the backbone in place with their ISO and other regulatory certifications, a fantastic quality system, and the regulatory processes all in place. We will be the recipients of those instead of having to take the years and the risks of building those out. It's really fantastic timing. As you pointed out, with them being at an inflection point for growth, bringing great capabilities to help us extend our biopharma relationships. Probably most importantly is that operation that's going to allow us to realize the value of the nCounter acquisition we did a couple of years ago. Just set up for incredible success. Bonnie, I know the nCounter one attribute was working with difficult samples was made easier. Any other insights you're gaining from nCounter? It's a fantastic technology and platform. Our team that has transitioned to Envisia loves the technology. I'll remind everyone who may not have been on our original call there, this was our top platform of choice to get access to take a distributive model to global markets so that we can test patients for all of our tests, eventually, perhaps, all over the world. The reason is it's a small footprint that fits into any laboratory. Turnaround times are about two days with one hour of hands-on time only by a technician. The complexity of the technology is all built into the cartridge, and it's very reliable, very easy to operate, yet highly capable with up to 800 genes, measures RNA, DNA, and protein. It gives us lots and lots of capability for our genomic tests. Now we'll be set up to accelerate that menu, build the products on our own, gain margins over time. Don't forget, NanoString makes margins on all these tests. Eventually, we'll have that margin. A pathway to growth and a pathway to operational solidification here. Just because this is one of the things that got me really excited about Veracyte and joining the company, when Bonnie and I talked about the strategy and these pieces all came together, having that kind of a platform with the full end-to-end control of the manufacturing, it puts us in a very differentiating position. Very excited about that. Thank you. I'm not showing any further questions at this time. Ladies and gentlemen, this concludes our call today. Thank you for joining us. You may now disconnect.